In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one tenth the standard dose.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Under the deal, which was first announced in September, Novartis will pay Arrowhead $200 million upfront. Arrowhead is eligible for additional payments of up to $2 billion tied to development, ...